Exploring combination treatment options for persistent methicillin-susceptible Staphylococcus aureus bacteremia
American Journal of Health-System Pharmacy · 10.02.2025 · 82 (4) · 150-163
DOI: 10.1093/ajhp/zxae252 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 04.09.2024. Verfasst von Hiba Al Shaikhli und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Mississippi Medical Center, Jackson, MS, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Staphylococcal Infections, Bacteremia, Staphylococcus aureus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben.
Abstract (Originalsprache)
Purpose
This review explores the management of persistent methicillin-susceptible Staphylococcus aureus bacteremia (SAB), emphasizing the importance of timely intervention due to SAB’s association with metastatic dissemination, relapse, and mortality. Summary The literature analysis first delves into risk factors for persistent SAB, highlighting the need for effective treatment strategies. The subsequent focus is on combination strategies for persistent SAB. Daptomycin, ertapenem, ceftaroline, fosfomycin, rifampin, and gentamicin are explored as adjuncts to cefazolin or antistaphylococcal penicillins. Daptomycin combination therapy is assessed through in vivo and clinical studies, indicating potential benefits, especially with higher-risk sources of infection. Ertapenem combination therapy has been demonstrated to have a synergistic effect with cefazolin, presenting a viable salvage option. Rifampin’s ability to penetrate biofilm is examined, with discussion of inconclusive evidence on mortality benefits. The review also considers stewardship implications, discussing concerns such as resistance emergence, adverse events, and increased costs associated with combination therapy. Mathematical models suggest combination therapy as an effective approach to prevent resistance. Adverse events vary with each combination, and duration of therapy remains diverse across studies in the absence of well-established dosing guidelines.
Conclusion
The review provides a thorough exploration of the literature on treatment of persistent SAB, underscoring the need for evidence-based guidelines, further studies, and clinical judgment in tailoring treatment strategies. The multifaceted analysis contributes valuable insights for clinicians managing this challenging condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Mississippi Medical Center, Jackson, MS, USA.
- Methodist Charlton Medical Center, Dallas, TX, USA.
- University of Mississippi, Jackson, MS, USA.
ORCID-Profile: Katie E Barber
Zitieren
APA
Al Shaikhli, H., Akins, R. L., Stover, K. R., & Barber, K. E. (2025). Exploring combination treatment options for persistent methicillin-susceptible Staphylococcus aureus bacteremia. American Journal of Health-System Pharmacy, 82(4), 150-163. https://doi.org/10.1093/ajhp/zxae252
Vancouver
Al Shaikhli H, Akins RL, Stover KR, Barber KE. Exploring combination treatment options for persistent methicillin-susceptible Staphylococcus aureus bacteremia. American Journal of Health-System Pharmacy. 2025;82(4):150-163. doi:10.1093/ajhp/zxae252
BibTeX
@article{AlShaikhli2025,
author = {Al Shaikhli, Hiba and Akins, Ronda L and Stover, Kayla R and Barber, Katie E},
title = {Exploring combination treatment options for persistent methicillin-susceptible Staphylococcus aureus bacteremia},
journal = {American Journal of Health-System Pharmacy},
year = {2025},
volume = {82},
number = {4},
pages = {150--163},
doi = {10.1093/ajhp/zxae252}
}
EUVIMED